---
schema_version: "secwatch.filing_event.v1"
accession: "0001595585-23-000023"
form_type: "8-K"
ticker: null
cik: "0001595585"
company_name: "Tricida, Inc."
filed_at: "2023-03-15T23:59:59+00:00"
generated_at: "2026-06-18T02:02:09.408605+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Tricida completes sale of Veverimer to Renibus for $250K upfront + up to $152.5M milestones

## Summary
- Asset sale closed March 9, 2023 after Bankruptcy Court approval on Feb 22.
- Upfront cash payment of $250,000; contingent milestones tied to FDA approval and net sales up to $152.5M.
- Company remains in Chapter 11 proceedings (Case No. 23-10024).
- Veverimer (TRC101) was Tricida's lead drug candidate for chronic kidney disease.

## SEC filing metadata
- accession: 0001595585-23-000023
- form_type: 8-K
- cik: 0001595585
- company_name: Tricida, Inc.
- filed_at: 2023-03-15T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595585/000159558523000023/0001595585-23-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595585/000159558523000023/tcda-20230309.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001595585-23-000023
- JSON: https://secwatch.observer/filing/0001595585-23-000023.json
- Plain text: https://secwatch.observer/filing/0001595585-23-000023.txt

## Key facts
- M&A Transactions
  Tricida, Inc. completed a disposition involving Renibus Therapeutics, Inc. for $250,000 at closing and certain contingent, milestone payments to the Company totaling up to $152.5 million (closed 2023-03-09).
  - Action: disposition
  - Counterparty: Renibus Therapeutics, Inc.
  - Consideration: $250,000 at closing and certain contingent, milestone payments to the Company totaling up to $152.5 million
  - Closing: 2023-03-09
  source text: agreed to acquire the intellectual property, inventory, and certain related assets relating to Veverimer (formerly known as TRC101) (the “Compound”) for a cash payment of $250,000 at closing and certain contingent, milestone payments to the Company totaling up to $152.5 million, subject to the achievement of certain United States Food and Drug
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595585/000159558523000023/0001595585-23-000023-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.